Bleeding Risk in Hemodialysis Patients

Cardiovascular diseases are highly prevalent among patients on dialysis. For these diseases, antiplatelets and antithrombotic therapies including heparin, vitamin K antagonists, and direct oral anticoagulants, are being used. However, the benefit–risk balance of these therapies could differ for dial...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Seminars in nephrology 2023-11, Vol.43 (6), p.151478, Article 151478
Hauptverfasser:	van Eck van der Sluijs, Anita, Pai, Pearl, Zhu, Wenjuan, Ocak, Gurbey
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticoagulants - adverse effects Anticoagulants - therapeutic use Antiplatelets bleeding Cardiovascular Diseases - etiology direct oral anticoagulants hemodialysis Hemorrhage - chemically induced Hemorrhage - etiology heparin Heparin - adverse effects Heparin - therapeutic use Humans Kidney Failure, Chronic - complications Kidney Failure, Chronic - therapy Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Renal Dialysis - adverse effects Risk Assessment Risk Factors Vitamin K - antagonists & inhibitors vitamin K antagonists
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Cardiovascular diseases are highly prevalent among patients on dialysis. For these diseases, antiplatelets and antithrombotic therapies including heparin, vitamin K antagonists, and direct oral anticoagulants, are being used. However, the benefit–risk balance of these therapies could differ for dialysis patients compared with the general population. This review article focuses on the bleeding risk associated with the use of heparin, antiplatelets, vitamin K antagonists, and direct oral anticoagulants in patients receiving hemodialysis.
ISSN:	0270-9295 1558-4488 1558-4488
DOI:	10.1016/j.semnephrol.2023.151478